Ticker Details
Evolus, Inc. Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
IPO Date:	February 5, 2018
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$554.16M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.39 | 3.46%
Avg Daily Range (30 D):	$0.22 | 3.25%
Avg Daily Range (90 D):	$0.20 | 3.17%

Institutional Daily Volume
Avg Daily Volume:	.64M
Avg Daily Volume (30 D):	.77M
Avg Daily Volume (90 D):	.74M

Trade Size
Avg Trade Size (Sh.):	106
Avg Trade Size (Sh.) (30 D):	73
Avg Trade Size (Sh.) (90 D):	74

Institutional Trades
Total Institutional Trades:	1,087
Avg Institutional Trade:	$1.35M
Avg Institutional Trade (30 D):	$.99M
Avg Institutional Trade (90 D):	$1.11M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.14M
Avg Closing Trade (30 D):	$.9M
Avg Closing Trade (90 D):	$1.13M
Avg Closing Volume:	104.79K

News

Jun 4, 2026 @ 11:00 AM AEON Biopharma to Present Data Demonstrating Struc... Source: Aeon Biopharma

May 22, 2026 @ 2:31 PM Regenerative Medicine's Newest Public Company Is B... Source: Usa News Group

Dec 28, 2025 @ 5:26 PM ANI Stock Is Up 49% This Past Year, Revenue Is Sur... Source: Jonathan Ponciano

Dec 19, 2025 @ 11:00 PM AEON Biopharma Reports Inducement Grants Under NYS... Source: Aeon Biopharma, Inc.

Mar 10, 2025 @ 8:53 PM Mixue Group's Splashy Debut, Kroger's Change, Stuf... Source: Dylan Lewis

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.53	$-.12	$-.16
Diluted EPS	$-.53	$-.12	$-.16
Revenue	$316.49M	$84.08M	$73.14M
Gross Profit	$211.21M	$57.18M	$48.9M
Net Income / Loss	$-34.33M	$-8.05M	$-10.67M
Operating Income / Loss	$-18.67M	$-4.54M	$-6.85M
Cost of Revenue	$105.28M	$26.9M	$24.24M
Net Cash Flow	$-16.57M	$-4.62M	$-4.03M
PE Ratio